The FDA has expanded the indications for the appointment of an oral janus kinase 1 inhibitor
.
Saved in:
Main Author: | article Editorial (Author) |
---|---|
Format: | Book |
Published: |
Union of pediatricians of Russia,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023) -
EMERGING USE OF JANUS KINASE INHIBITORS FOR ORAL LICHEN PLANUS
by: Mihaela Paula Toader, et al.
Published: (2024) -
Janus kinase inhibitors: jackpot or potluck?
by: Pavithran Keechilat, et al.
Published: (2012) -
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
by: Annie Mayence, et al.
Published: (2019) -
Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
by: Fabienne Ballanger, et al.
Published: (2023)